N/A
Manufactured by Actavis Pharma, Inc.
14,012 FDA adverse event reports analyzed
Last updated: 2026-04-15
DESONIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Actavis Pharma, Inc.. The most commonly reported adverse reactions for DESONIDE include DRUG INEFFECTIVE, MACULAR DEGENERATION, OFF LABEL USE, PAIN, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DESONIDE.
Out of 4,710 classified reports for DESONIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 14,012 FDA FAERS reports that mention DESONIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, MACULAR DEGENERATION, OFF LABEL USE, PAIN, NAUSEA, HEADACHE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Actavis Pharma, Inc. in connection with DESONIDE. Always verify the specific product and NDC with your pharmacist.